Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Vipadenant
Cat. No.:
0225LY-0646
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Vipadenant acts as an adenosine A2a antagonist (Ki: 1.3 nM) and shows significantly lower affinity for the A1 receptor (Ki: 69 nM).
Synonym:
442908-10-3; 3-(4-amino-3-methylbenzyl)-7-(furan-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine; 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine; 3-(4-Amino-3-methylbenzyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine; 3-[(4-azanyl-3-methyl-phenyl)methyl]-7-(furan-2-yl)-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine; 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine
CAS No.:
442908-10-3
Compound CID:
21874557
Formula:
C16H15N7O
Formula Weight:
321.34
Specification
Targets&IC50:
A1: 69 nM(Ki); A2A: 1.3 nM(Ki)
Relative Density:
1.56 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Vipadenant can be used in neuropharmacology to study the selective antagonism of the A2A adenosine receptor.
Library Information
Target:
Adenosine receptor
Receptor:
A1; A2A; A3
Pathways:
GPCR/G protein signaling; Neuronal signaling
Plate Number:
AOCL-9
Plate Location:
d2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 171.16 mM
